Abstract:Spinal Muscular Atrophy (SMA) is the leading genetic cause of infant mortality. The most common form of SMA is caused by mutations in the SMN1 gene, located on 5q (SMA). On the other hand, mutations in IGHMBP2 lead to a large disease spectrum with no clear genotype–phenotype correlation, which includes Spinal Muscular Atrophy with Muscular Distress type 1 (SMARD1), an extremely rare form of SMA, and Charcot–Marie–Tooth 2S (CMT2S). We optimized a patient-derived in vitro model system that allows us to expand research on disease pathogenesis and gene function, as well as test the response to the AAV gene therapies we have translated to the clinic. We generated and characterized induced neurons (iN) from SMA and SMARD1/CMT2S patient cell lines. After establishing the lines, we treated the generated neurons with AAV9-mediated gene therapy (AAV9.SMN (Zolgensma) for SMA and AAV9.IGHMBP2 for IGHMBP2 disorders (NCT05152823)) to evaluate the response to treatment. The iNs of both diseases show a characteristic short neurite length and defects in neuronal conversion, which have been reported in the literature before with iPSC modeling. SMA iNs respond to treatment with AAV9.SMN in vitro, showing a partial rescue of the morphology phenotype. For SMARD1/CMT2S iNs, we were able to observe an improvement in the neurite length of neurons after the restoration of IGHMBP2 in all disease cell lines, albeit to a variable extent, with some lines showing better responses to treatment than others. Moreover, this protocol allowed us to classify a variant of uncertain significance on IGHMBP2 on a suspected SMARD1/CMT2S patient. This study will further the understanding of SMA, and SMARD1/CMT2S disease in particular, in the context of variable patient mutations, and might further the development of new treatments, which are urgently needed.

From data to discovery: AI-guided analysis of disease-relevant molecules in spinal muscular atrophy (SMA)

The systemic complexity of a monogenic disease: the molecular network of spinal muscular atrophy

Identification of Novel Biomarkers of Spinal Muscular Atrophy and Therapeutic Response by Proteomic and Metabolomic Profiling of Human Biological Fluid Samples

Spinal Muscular Atrophy Modeling and Treatment Advances by Induced Pluripotent Stem Cells Studies

Discovery, synthesis, and biological evaluation of novel SMN protein modulators

Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy

An interpretable data-driven prediction model to anticipate scoliosis in spinal muscular atrophy in the era of (gene-) therapies

Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy

Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era

RNA-based drug discovery for spinal muscular atrophy: a story of small molecules and antisense oligonucleotides

A high-throughput genome-wide RNAi screen identifies modifiers of survival motor neuron protein

Identifying Biomarkers of Spinal Muscular Atrophy for Further Development

In Vitro Modeling as a Tool for Testing Therapeutics for Spinal Muscular Atrophy and IGHMBP2-Related Disorders

Therapeutic strategy for spinal muscular atrophy by combining gene supplementation and genome editing

The SMN-ribosome interplay: a new opportunity for Spinal Muscular Atrophy therapies

Gene Therapy: A Promising Approach to Treating Spinal Muscular Atrophy

In Search of Spinal Muscular Atrophy Disease Modifiers

LCM-seq reveals unique transcriptional adaptation mechanisms of resistant neurons and identifies protective pathways in spinal muscular atrophy

Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy

Recent Advance in Disease Modifying Therapies for Spinal Muscular Atrophy

A large animal model of spinal muscular atrophy and correction of phenotype